Febit Achieves Sales Goals
News Mar 16, 2006
Febit biotech gmbh has announced that it has successfully concluded the business year, meeting its sales goals for 2005.
Sales of GENIOM™, a biochip-driven nucleic acid analysis system, were on budget already in the year of Febit's re-establishment.
This development is based on the fundamental restructuring and re-establishment of Febit biotech gmbh in spring 2005 when the company moved into new quarters in the Heidelberg Technologiepark.
Since its reorganization, Febit is supported by Dietmar and Oliver Hopp, two experienced biotech investors interested in a favourable long-term development of the company.
Integrating its structural and financial basis, Febit's re-establishment was supported by Prof. Christof Hettich, an experienced consultant from the Rittershaus firm of Mannheim.
In October 2005 the management team around Cord F. Stahler, CEO of Febit biotech gmbh was expanded, a supervisory board was established and the headcount was gradually increased.
The team consisting of management, staff and supervisory board boasts know-how and skills in all relevant areas.
Febit has become a valuable cooperation partner in the biotech field, which is illustrated by a number of licence agreements signed in late 2005.
From Oxford Gene Technology, Febit acquired a license for the southern array technique, a method of major impact in gene research, thus enhancing its position with respect to intellectual property on the global market.
In a license agreement with the German Cancer Reseach Center (DKFZ), Febit acquired the rights to an alternative high-efficacy DNA synthesis method for use in its GENIOM® platform.
Dr. Jorg Hoheisel at the DKFZ strongly supports the GENIOM® platform, said, "This DNA analysis device offers tremendous flexibility and has an extraordinary potential. It is invaluable for many aspects of our work at the DKFZ."
In February 2005, the Febit facilities were substantially enlarged and the headcount will reach 50 at the end of 2006 in order to realize the expansion plans and to ensure reliable product quality and availability.
Cord F. Stahler, Chief Executive Officer of Febit biotech gmbh is confident to generate substantial growth within 2006, "The changes we made in 2005 and our network allow us to rapidly expand our position on the international market."
"The global market of DNA analysis devices will keep growing substantially in the next years. Febit will participate in this growth due to significant product advantages and the market-readiness of GENIOM®."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.